HomeExamplesMCP & ModelsResearchDocumentationLoginBook a demo
HomeExamplesMCP & ModelsResearchDocumentationLoginBook a demo

Oregon Therapeutics

Ownership
Private
Therapeutic Areas
Oncology
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Small molecules

Oregon Therapeutics General Information

XCE853 has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple cancer types, and is ready to advance to Investigational New Drug (IND)-enabling development[2]

Contact Information

Website
https://oregon-therapeutics.com/
Primary Industry
Biotech
Corporate Office
Paris,
France

Drug Pipeline

XCE853
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Oregon Therapeutics's pipeline data

Book a demo

Key Partnerships

Lantern Pharma Inc. (NASDAQ: LTRN)[2]

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Oregon Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Oregon Therapeutics's complete valuation and funding history, request access »

Oregon Therapeutics Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals